3710-50-7

Usage

InChI:InChI=1/C13H14O4/c1-4-16-13(14)12-8(2)10-7-9(15-3)5-6-11(10)17-12/h5-7H,4H2,1-3H3

Upstream product

• 33038-04-9 ethyl 2-(2-acetyl-4-methoxyphenoxy)acetate 
• 13246-19-0 (2-acetyl-5-methoxy-phenoxy)-acetic acid ethyl ester 
• 705-15-7 1-(2-hydroxy-5-methoxyphenyl)ethan-1-one 
• 150-76-5 4-methoxy-phenol 
• 609-15-4 ethyl 2-chloro-3-oxo-butyrate 
• 7699-85-6 ethyl 2-(4-methoxyphenoxy)-3-oxobutanoate 

Relevant academic research and scientific papers

NEW DIHYDRO-OXAZINOBENZODIAZEPINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITONS CONTAINING THEM

Compounds of formula (I) having a selective dual action on the central GABAergic system, and a process for their preparation and to pharmaceutical compositions containing them.

NEW DIHYDRO-OXAZINOBENZODIAZEPINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I) wherein R1, R2 are independently selected from hydrogen and Cu alkyl; R3 is hydrogen or C1-4 alkyl group which is unsubstituted or substituted by phenyl, pyridyl, or amino optionally substituted by C1-4 alkyl; R4 is hydrogen; R5 is C1-4 alkyl group; R6 is selected from monocyclic aryl, which is a six membered ring unsubstituted or substituted by one or more identical or different groups selected from C1-4 alkyl groups, C1-4 alkoxy, halogenated C1-4 alkyl, phenyl, phenoxy, halogen, nitro; or mono- or bi- or tricyclic heteroaryl group consisting of five or six membered ring(s) having 1 to 3 identical or different hetero atoms selected from nitrogen, oxygen and sulfur, in which at least one of the rings is aromatic, and wherein the rings are optionally substituted by one or more identical or different groups selected from C1-4 alkyl, mono-, di-, tri- halogenated C1-4 alkyl, C1-4 alkoxy, hydroxyl, halogen; their positional isomers, racemates and enantiomers, diastereoisomers, and addition salts with a pharmaceutically acceptable acid, solvates, their complexes, adducts and prodrugs, having a selective dual action on the central GABAergic system, to a process for their preparation and to pharmaceutical compositions containing them.

CYSTEINE PROTEASE INHIBITORS

A compound of the formula (II) wherein one of R1 and R2 is halo and the other is H or halo; R3 is C1-C4 straight or branched chain, optionally fluorinated, alkyl; R4 is H; or R3 together with R4 and the adjoining backbone carbon defines: a spiro-C5-C7 cycloalkyl, optionally substituted with 1 to 3 substituents selected from halo, hydroxyl, C1-C4 alkyl or C1-C4 haloalkyl; or optionally bridged with a methylene group; or a C4-C6 saturated heterocycle having a hetero atom selected from O, NRa, S, S(=O)2 ; where Ra is H, C1-C4 alkyl or CH3C(=O); R5 is independently selected from H or methyl; E is -C(=O)-, -S(=O)m-, -NR5S(=O)m-, -NR5C(=O)-, -OC(=O)-, R6 is a stable, optionally substituted, monocyclic or bicyclic, carbocycle or hetorocycle; m is independently 0,1 or 2; are inhibitors of cathepsin K and useful in the treatment or prophylaxis of osteoporosis.

Benzofuran Derivatives. Part 4. Synthesis of Benzofurans and 2,3,4,5-Tetrahydro-1-benzoxepin-3,5-diones

By treatment of ethyl 4- or 5-substituted 2-acetylphenoxyacetates 1 with potassium hydroxide in dry dioxane, benzofurans 2-7 and 2,3,4,5-tetrahydro-1-benzoxepin-3,5-diones 8 were obtained.The relative yields of benzofurans 2-7 and 2,3,4,5-tetrahydro-1-benzoxepin-3,5-diones 8 varied with the types of 4- or 5-substituents.The electron-donating 4-methoxyl group favored the formation of benzoxepins.On the other hand, electron-withdrawing substituents such as the 4-nitro group favored the formation of benzofurans.When esters 1 were treated with sodium amide,2,3-dihydrobenzofurans 2 were obtained exclusively regardless of 4- or 5-substituents.